Literature DB >> 21703400

Plexiform lesions in pulmonary arterial hypertension composition, architecture, and microenvironment.

Danny Jonigk1, Heiko Golpon, Clemens L Bockmeyer, Lavinia Maegel, Marius M Hoeper, Jens Gottlieb, Nils Nickel, Kais Hussein, Ulrich Maus, Ulrich Lehmann, Sabina Janciauskiene, Tobias Welte, Axel Haverich, Johanna Rische, Hans Kreipe, Florian Laenger.   

Abstract

Pulmonary arterial hypertension (PAH) is a debilitating disease with a high mortality rate. A hallmark of PAH is plexiform lesions (PLs), complex vascular formations originating from remodeled pulmonary arteries. The development and significance of these lesions have been debated and are not yet fully understood. Some features of PLs resemble neoplastic disorders, and there is a striking resemblance to glomeruloid-like lesions (GLLs) in glioblastomas. To further elucidate PLs, we used in situ methods, such as (fluorescent) IHC staining, three-dimensional reconstruction, and laser microdissection, followed by mRNA expression analysis. We generated compartment-specific expression patterns in the lungs of 25 patients (11 with PAH associated with systemic shunts, 6 with idiopathic PAH, and 8 controls) and GLLs from 5 glioblastomas. PLs consisted of vascular channels lined by a continuously proliferating endothelium and backed by a uniform myogenic interstitium. They also showed up-regulation of remodeling-associated genes, such as HIF1a, TGF-β1, VEGF-α, VEGFR-1/-2, Ang-1, Tie-2, and THBS1, but also of cKIT and sprouting-associated markers, such as NOTCH and matrix metalloproteinases. The cellular composition and signaling seen in GLLs in neural neoplasms differed significantly from those in PLs. In conclusion, PLs show a distinct cellular composition and microenvironment, which contribute to the plexiform phenotype and set them apart from other processes of vascular remodeling in patients with PAH. Neoplastic models of angiogenesis seem to be of limited use in further study of plexiform vasculopathy.
Copyright © 2011 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21703400      PMCID: PMC3123793          DOI: 10.1016/j.ajpath.2011.03.040

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  52 in total

Review 1.  Pulmonary hypertension in autoimmune rheumatic diseases.

Authors:  Patricia E Carreira
Journal:  Autoimmun Rev       Date:  2004-06       Impact factor: 9.754

2.  Transdifferentiation of pulmonary arteriolar endothelial cells into smooth muscle-like cells regulated by myocardin involved in hypoxia-induced pulmonary vascular remodelling.

Authors:  Pengcheng Zhu; Lei Huang; Xiaona Ge; Fei Yan; Renliang Wu; Qilin Ao
Journal:  Int J Exp Pathol       Date:  2006-12       Impact factor: 1.925

3.  Obliterative airway remodeling: molecular evidence for shared pathways in transplanted and native lungs.

Authors:  Danny Jonigk; Marlene Merk; Kais Hussein; Lavinia Maegel; Katharina Theophile; Michaela Muth; Ulrich Lehmann; Clemens L Bockmeyer; Michael Mengel; Jens Gottlieb; Tobias Welte; Axel Haverich; Heiko Golpon; Hans Kreipe; Florian Laenger
Journal:  Am J Pathol       Date:  2011-02       Impact factor: 4.307

4.  Dysregulation of the IL-13 receptor system: a novel pathomechanism in pulmonary arterial hypertension.

Authors:  Matthias Hecker; Zbigniew Zaslona; Grazyna Kwapiszewska; Gero Niess; Anna Zakrzewicz; Eduard Hergenreider; Jochen Wilhelm; Leigh M Marsh; Daniel Sedding; Walter Klepetko; Jürgen Lohmeyer; Stefanie Dimmeler; Werner Seeger; Norbert Weissmann; Ralph T Schermuly; Nikolaus Kneidinger; Oliver Eickelberg; Rory E Morty
Journal:  Am J Respir Crit Care Med       Date:  2010-06-03       Impact factor: 21.405

5.  Vascular smooth muscle cell phenotypes in primary pulmonary hypertension.

Authors:  Y Mitani; M Ueda; R Komatsu; K Maruyama; R Nagai; M Matsumura; M Sakurai
Journal:  Eur Respir J       Date:  2001-02       Impact factor: 16.671

6.  Obliterative airway remodelling in transplanted and non-transplanted lungs.

Authors:  Danny Jonigk; Katharina Theophile; Kais Hussein; Oliver Bock; Ulrich Lehmann; Clemens L Bockmeyer; Jens Gottlieb; Stefan Fischer; Andre Simon; Tobias Welte; Lavinia Maegel; Hans Kreipe; Florian Laenger
Journal:  Virchows Arch       Date:  2010-07-15       Impact factor: 4.064

7.  Bone morphogenetic protein (BMP)-4 and BMP-7 regulate differentially transforming growth factor (TGF)-beta1 in normal human lung fibroblasts (NHLF).

Authors:  Sophie Pegorier; Gaynor A Campbell; A Barry Kay; Clare M Lloyd
Journal:  Respir Res       Date:  2010-06-23

Review 8.  Crosstalk between vascular endothelial growth factor, notch, and transforming growth factor-beta in vascular morphogenesis.

Authors:  Matthew T Holderfield; Christopher C W Hughes
Journal:  Circ Res       Date:  2008-03-28       Impact factor: 17.367

9.  Resistin-like molecule-beta in scleroderma-associated pulmonary hypertension.

Authors:  Daniel J Angelini; Qingning Su; Kazuyo Yamaji-Kegan; Chunling Fan; Xingwu Teng; Paul M Hassoun; Stephen C Yang; Hunter C Champion; Rubin M Tuder; Roger A Johns
Journal:  Am J Respir Cell Mol Biol       Date:  2009-02-27       Impact factor: 6.914

10.  Contact-inhibited chemotaxis in de novo and sprouting blood-vessel growth.

Authors:  Roeland M H Merks; Erica D Perryn; Abbas Shirinifard; James A Glazier
Journal:  PLoS Comput Biol       Date:  2008-09-19       Impact factor: 4.475

View more
  60 in total

1.  [Aberrant reparative tissue remodeling: histopathology and molecular pathology].

Authors:  D Jonigk
Journal:  Pathologe       Date:  2014-11       Impact factor: 1.011

2.  [Histopathological aspects of pulmonary hypertension].

Authors:  D Jonigk; M M Hoeper; H Kreipe; F Länger
Journal:  Pathologe       Date:  2012-05       Impact factor: 1.011

Review 3.  Inflammation in Pulmonary Arterial Hypertension.

Authors:  Timothy Klouda; Ke Yuan
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 4.  Drug abuse and HIV-related pulmonary hypertension: double hit injury.

Authors:  Zachery J Harter; Stuti Agarwal; Pranjali Dalvi; Norbert F Voelkel; Navneet K Dhillon
Journal:  AIDS       Date:  2018-11-28       Impact factor: 4.177

Review 5.  Pathophysiology and treatment of pulmonary hypertension in sickle cell disease.

Authors:  Victor R Gordeuk; Oswaldo L Castro; Roberto F Machado
Journal:  Blood       Date:  2016-01-12       Impact factor: 22.113

6.  Involvement of endothelial progenitor cells in the formation of plexiform lesions in broiler chickens: possible role of local immune/inflammatory response.

Authors:  Xun Tan; Fan-Guo Juan; Ali Q Shah
Journal:  J Zhejiang Univ Sci B       Date:  2017 Jan.       Impact factor: 3.066

7.  Enhanced caveolin-1 expression in smooth muscle cells: Possible prelude to neointima formation.

Authors:  Jing Huang; John H Wolk; Michael H Gewitz; James E Loyd; James West; Eric D Austin; Rajamma Mathew
Journal:  World J Cardiol       Date:  2015-10-26

Review 8.  Steps forward in the treatment of pulmonary arterial hypertension: latest developments and clinical opportunities.

Authors:  Jessica B Badlam; Todd M Bull
Journal:  Ther Adv Chronic Dis       Date:  2017-03-01       Impact factor: 5.091

9.  Modulating the dysregulated migration of pulmonary arterial hypertensive smooth muscle cells with motif mimicking cell permeable peptides.

Authors:  Jamie L Wilson; Chamila Rupasinghe; Anny Usheva; Rod Warburton; Chloe Kaplan; Linda Taylor; Nicholas Hill; Dale F Mierke; Peter Polgar
Journal:  Curr Top Pept Protein Res       Date:  2015

10.  Nitration of tyrosine 247 inhibits protein kinase G-1α activity by attenuating cyclic guanosine monophosphate binding.

Authors:  Saurabh Aggarwal; Christine M Gross; Ruslan Rafikov; Sanjiv Kumar; Jeffrey R Fineman; Britta Ludewig; Danny Jonigk; Stephen M Black
Journal:  J Biol Chem       Date:  2014-01-27       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.